21 articles about Symcel
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Symcel – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås.
Symcel partners with Karolinska Institutet to validate calScreener™ in clinical antimicrobial susceptibility testing
Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™ – has partnered with the Karolinska Institutet in a Horizon 2020 funded project.
Symcel Expands Staff for Clinical Market Growth and Horizon 2020 Funded Validation of Antimicrobial Susceptibility Testing
Symcel is expanding to bring its patented technology to the clinical antimicrobial susceptibility testing markets.
Symcel Secures €3.6 Million Horizon 2020 Phase II Grant for Clinical Validation of Customized Antimicrobial Susceptibility Testing Multi-Resistant Bacterial Sepsis Infections to be Validated Utilising Symcel's Sensitive Screening Technology
The project runs over 28 months with a consortium of internationally recognized academic and clinical key opinion leaders from Karolinska Institutet, Hospital Universitario Ramón y Cajal, Careggi University Hospital, Rigshospitalet, IHE and Symcel.
Symcel: Calorimetry-Based 3D Phenotype Assays: A Necessity For Drug Discovery And Personalized Medicine
Symcel And Colzyx Partner To Test 25 Novel, First-In-Kind Collagen VI Derived Anti Microbial Peptides With calScreener
Symcel, Tika Diagnostics And St. George's University Of London Form Partnership To Use Calscreener In Anti Microbial Susceptibililty Testing
Symcel Secures Phase I Horizon 2020 Grant As The Company Plans For Full Scale Commercialisation Of calScreener – The World’s First Multi Channel Calorimetry System For Antimicrobial Susceptibility Testing
Symcel Expands The Diverse Range Of Biological Applications Of Its Ground Breaking Assay Tool – The Calscreener Calorimeter
Symcel Unveils Cellular Bio-Energetics Solutions That Enhance Phenotype Based Drug Discovery At The 2016 NovAliX Conference
Symcel Secures SK 5.6 Million As Further Investment To Fund Marketing And Business Development Initiatives
Symcel: Fighting Antibiotic Resistance With Calorimetry New Tools For Better Antimicrobial Drug Development
Symcel Unveils International Installation Of Its Innovative Calscreener Technology Across Sweden, Switzerland, South Africa, Holland And Germany And South East Asia With Wide Ranging Applications
Symcel’s Technology Opens New Research Avenues In Cancer Research, Diagnostics And The Development Of New Anti-Tumour Drugs